Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2026-03-26 Remuneration Information
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
BioPorto announces the Annual Report for 2025
Remuneration Information Classification · 93% confidence The document is a standalone “2025 Remuneration Report” for BioPorto A/S detailing the remuneration policy, fees paid to the Board of Directors, Executive Management compensation elements, warrant programs, and related disclosures prepared under section 139b of the Danish Companies Act. This matches the definition of “Remuneration Information” (Code: DEF 14A), which covers detailed compensation reports for executives and directors.
2026-03-26 English
BioPorto announces the Annual Report for 2025
Report Publication Announcement Classification · 88% confidence The document is a GlobeNewswire press release that summarizes FY 2025 financial highlights and strategic achievements, and provides links to download the full Annual Report and related documents. It does not contain the complete Annual Report but rather announces its publication and availability. Therefore, under the “menu vs meal” rule, this is a Report Publication Announcement.
2026-03-26 English
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from BioPorto regarding the positive results of a clinical study and the upcoming FDA pre-submission process. It is a regulatory announcement (Meddelelse no. 03) issued to the market to provide a business update. Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a general corporate update, it is classified as a Regulatory Filing (RNS).
2026-03-18 Danish
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from BioPorto A/S regarding the results of a clinical study and upcoming regulatory filings. It is structured as a press release/regulatory announcement (Meddelelse no. 03). While it discusses clinical trial results, it is not a full audit report or a financial report. It functions as a general regulatory update for shareholders and the market. Given the 'Menu vs Meal' rule, although it contains a link to a PDF, the text itself is a standard regulatory announcement (RNS) providing a summary of company developments.
2026-03-18 Danish
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings Classification · 95% confidence The document is a corporate announcement regarding the clinical progress of a medical study (NGAL Cutoff Study) and upcoming FDA regulatory interactions. It does not constitute a financial report, audit, or shareholder meeting material. As it is a general regulatory announcement regarding company operations and clinical milestones that does not fit into specific categories like M&A or dividends, it is classified as a general regulatory filing.
2026-03-18 English
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
Regulatory Filings Classification · 95% confidence The document is a press release from BioPorto A/S announcing the completion of a preliminary analysis for a clinical study. It is a short, news-style announcement (under 8,000 characters) that includes a link to an attached PDF report. According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the clinical study report itself. Therefore, it is classified as a Report Publication Announcement (RPA).
2026-03-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.